Doctors Recommend A New Treatment For Cancer

Doctors Recommend A New Treatment For Cancer.

The dope Arimidex reduces the endanger of developing breast cancer by more than 50 percent among postmenopausal women at pongy risk for the disease, according to a new study Dec 2013. The finding, scheduled for bestowal Thursday at the San Antonio Breast Cancer Symposium in Texas, adds ambition that Arimidex (anastrozole) might be a valuable new preventive option for some women The analysis will also be published in the journal The Lancet.

So "Two other antihormone therapies, tamoxifen and raloxifene, are cast-off by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which bridle their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research red lips k liye kya kre. "Hopefully, our findings will vanguard to an alternative prevention therapy with fewer minor effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, source of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

About 80 percent of US heart cancer patients have tumors with turned on levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore second-hand to treat postmenopausal women with hormone receptor-positive chest cancer. The study included more than 3800 postmenopausal women at increased jeopardy for breast cancer due to having two or more blood relatives with breast cancer, having a dam or sister who developed breast cancer before age 50, or having a native or sister who had breast cancer in both breasts.

About half the women took Arimidex for five years while the others took a placebo, or also phony drug. Those who took the drug were 53 percent less disposed to to develop breast cancer than those who took the placebo. Side effects among the women taking the poison included hot flashes and small increases in muscle aches and pains. The boning up received funding from the drug companies AstraZeneca and Sanofi-Aventis, and Cuzick is on the speaker's chest of drawers for AstraZeneca.

Two breast cancer experts in the United States expressed optimism about the new findings. "This is very overpowering information," said Dr Amy Tiersten, associate professor of medicament at the Icahn School of Medicine at Mount Sinai, in New York City. She said that although tamoxifen and raloxifene can also condense a woman's odds for breast cancer, "these medications can a little increase the risk of blood clots and uterine cancer.

It is great to have a less toxic option to offer patients in the preventative arena," she said of Arimidex. Dr Stephanie Bernik, premier of surgical oncology at Lenox Hill Hospital in New York City, agreed. "It is with inaugurate arms that we can total Arimidex to the medications that can be offered to postmenopausal women that are at high risk of developing mamma cancer.

So "Because Arimidex has less side effects, more women are likely to undergo preventive treatment. This will in due course help decrease the incidence of breast cancer in women in this category. We are planning to proceed following the study participants for at least 10 years, and hopefully much longer," scan author Cuzick said tryvimax. "We want to determine if Arimidex has a continued impact on cancer amount even after stopping treatment, if it reduces deaths from breast cancer, and to ensure that there are no long-term adverse marginal effects".

tag : cancer breast women arimidex effects postmenopausal study cuzick treatment

Post a comment

Private comment



Welcome to FC2!

Latest journals
Latest comments
Latest trackbacks
Monthly archive
Search form
Display RSS link.
Friend request form

Want to be friends with this user.